Liquid Chromatographic Determination of Glyoxal and Methylglyoxal from Serum of Diabetic Patients using Meso‐Stilbenediamine as Derivatizing Reagent

Abstract

Meso‐stilbenediamine has been used as derivatizing reagent for liquid chromatographic (LC) determination of glyoxal (Go), methylglyoxal (MGo), and dimethylglyoxal (DMGo) at pH 3. Liquid chromatographic elution and separation was carried out from the column Kromasil 100 C‐18, 5 µm (15×0.46 mm i.d.) with methanol: water:acetonitrile (59:40:1, v/v/v) with a flow rate of 1 mL/min and ultraviolet detection at 254 nm. The linear calibration curves were obtained for Go, MGo, and DMGo within 0.97–4.86 µg/mL, 1.52–7.6 µg/mL, and 1.41–7.08 µg/mL with detection limits of 48 ng/mL, 76 ng/mL, and 70.8 ng/mL, respectively. The method was applied for the determination of Go and MGo from serum of patients suffering from diabetes and ketosis. The amounts of Go and MGo found were 0.150–0.260 µg/mL and 0.160–0.270 µg/mL with coefficient of variation (C.V.) 2.6–4.7% and 2.5–4.6%, respectively. The results obtained were compared with normal subjects with Go and MGo contents of 0.025–0.065 µg/mL and 0.030–0.070 µg/mL with C.V 1.5–4.9% and 1.6–4.8% in the serum.     

Utility of Certain π‐Acceptors for the Spectrophotometric Determination of Tranexamic Acid in Commercial Dosage Forms

Abstract

In this study, two simple, fast, accurate, and sensitive spectrophotometric methods have been developed for the determination of tranexamic acid in commercial dosage forms. These methods (A and B) are based on the reaction of tranexamic acid as n‐electron donor with 2,3‐dichloro‐5,6‐dicyano‐1,4‐benzoquinone (DDQ) and 7,7,8,8‐tetracyanoquinodimethane (TCNQ) as π‐acceptors to give highly colored complex species that absorb maximally at 470 and 750 nm, respectively. Beer's law was obeyed in the concentration limit of 0.5–10 µg/mL for tranexamic acid. The limit of detection (LOD) and limit of quantification (LOQ) were calculated and found to be 0.18 µg/mL and 0.60 µg/mL for method A and 0.12 µg/mL and 0.39 µg/mL for method B, respectively. A Job's plot of the absorbance versus the molar ratio of tranexamic acid to each of the acceptors under consideration indicated 1∶1. The proposed methods were found to be rapid, accurate, precise, and sensitive for the determination of tranexamic acid in commercial dosage forms without interferences from common additives encountered.     

Validated LC‐MS method for simultaneous quantitation of catalpol and harpagide in rat plasma: application to a comparative pharmacokinetic study in normal and diabetic rats after oral administration of Zeng‐Ye‐Decoction

A simple and efficient liquid chromatography‐mass spectrometry (LC‐MS) method was developed and validated for simultaneous quantitation of catalpol and harpagide in normal and diabetic rat plasma. Protein precipitation extraction with acetonitrile was carried out using salidroside as the internal standard (IS). The LC separation was performed on an Elite C₁₈ column (150 × 4.6 mm, 5 µm) with the mobile phase consisting of acetonitrile and water within a runtime of 12.0 min. The analytes were detected without endogenous interference in the selected ion monitoring mode with positive electrospray ionization. Calibration curves offered satisfactory linearity (r > 0.99) at linear range of 0.05–50.0 µg/mL for catalpol and 0.025–5.0 µg/mL for harpagide with the lower limits of quantitation of 0.05 and 0.025 µg/mL, respectively. Intra‐ and inter‐day precisions (RSD) were <9.4%, and accuracy (RE) was in the ?6.6 to 4.9% range. The extraction efficiencies of catalpol, harpagide and IS were all >76.5% and the matrix effects of the analytes ranged from 86.5 to 106.0%. The method was successfully applied to the pharmacokinetic study of catalpol and harpagide after oral administration of Zeng‐Ye‐Decoction to normal and diabetic rats, respectively. Copyright © 2013 John Wiley & Sons, Ltd.     

A reliable method of liquid chromatography for the quantification of acetaminophen and identification of its toxic metabolite N-acetyl-p-benzoquinoneimine for application in pediatric studies

The aim of the present study was to develop a simple, selective and reliable method to quantify acetaminophen and its toxic metabolite N‐acetyl‐p‐benzoquinoneimine (NAPQI) for pediatric studies using 100 µL plasma samples, by reverse‐phase HPLC and UV detection. The assay was performed using a C₁₈ column and an isocratic elution with water–methanol–formic acid (70:30:0.15; v/v/v) as mobile phase. Linearity of the method was assayed in the range of 1–30 µg/mL for acetaminophen and 10–200 µg/mL for NAPQI, with a correlation coefficient r = 0.999 for both compounds, and inter‐ and intra‐day coefficients of variation of less than 13%. Several commonly co‐administered drugs were analyzed for selectivity and no interference with the determinations was observed. The detection and quantification limits for acetaminophen and NAPQI were 0.1 and 1 µg/mL, and 0.1 and 10 µg/mL respectively. The present method can be used to monitor acetaminophen levels using 100 µL plasma samples, which may be helpful when very small samples need to be analyzed, as in pharmacokinetics determination or drug monitoring in plasma in children. This assay is also able to detect the NAPQI for drug monitoring in patients diagnosed with acetaminophen intoxication. Copyright © 2010 John Wiley & Sons, Ltd.     

Vortex‐assisted liquid–liquid micro‐extraction and high‐performance liquid chromatography for a higher sensitivity methyl methacrylate determination in biological matrices

A vortex‐assisted liquid–liquid micro‐extraction coupled with high‐performance liquid chromatography, with UV–vis, is proposed to pre‐concentrate methyl methacrylate and to improve separation in biological matrices. The use of 1‐octanol as extracting phase, its volume, the need for a dispersant agent, the agitation conditions and the cooling time before phase separation were evaluated. In optimum conditions, enrichment factors of 20 (±0.5) and enrichment recovery of 99% were obtained. The straightforward association of this extraction process with the HPLC method, previously regulated by the International Organization for Standardization, afforded a detection limit of 122 ng/mL and a quantification limit of 370 ng/mL. The within‐batch precision, relative standard deviation, was 3% for a sample with 1.49 µg/mL and 4% for a sample with 13.4 µg/mL. The results showed a between batch‐precision of 21% for experiments performed on five different days, for a sample with a concentration of 1.10 µg/mL in methyl methacrylate. Copyright © 2013 John Wiley & Sons, Ltd.     

Determination of Cefalothin and Cefazolin in Human Plasma,Urine and Peritoneal Dialysate by UHPLC‐MS/MS: application to a pilot pharmacokinetic study in humans

An ultra‐high‐performance liquid chromatography–tandem mass spectrometry (UHPLC‐MS/MS) method for the analysis of cefazolin and cefalothin in human plasma (total and unbound), urine and peritoneal dialysate has been developed and validated. Total plasma concentrations are measured following protein precipitation and are suitable for the concentration range of 1–500 µg/mL. Unbound concentrations are measured from ultra‐filtered plasma acquired using Centrifree^® devices and are suitable for the concentration range of 0.1–500 µg/mL for cefazolin and 1–500 µg/mL for cefalothin. The urine method is suitable for a concentration range of 0.1–20 mg/mL for cefazolin and 0.2–20 mg/mL for cefalothin. Peritoneal dialysate concentrations are measured using direct injection, and are suitable for the concentration range of 0.2–100 µg/mL for both cefazolin and cefalothin. The cefazolin and cefalothin plasma (total and unbound), urine and peritoneal dialysate results are reported for recovery, inter‐assay precision and accuracy, and the lower limit of quantification, linearity, stability and matrix effects, with all results meeting acceptance criteria. The method was used successfully in a pilot pharmacokinetic study with patients with peritoneal dialysis‐associated peritonitis, receiving either intraperitoneal cefazolin or cefalothin. Copyright © 2015 John Wiley & Sons, Ltd.     

Combined derivatization and high‐performance liquid chromatography with fluorescence and ultraviolet detection for simultaneous analysis of octreotide and gabexate mesylate metabolite in human pancreatic juice samples

A simple and sensitive method based on the combination of derivatization and high‐performance liquid chromatography with ultraviolet and fluorimetric detection was developed for the simultaneous determination of octreotide and gabexate mesylate metabolite in human pancreatic juice samples. Parameters of the derivatization procedure affecting extraction efficiency were optimized. The developed method was validated according to the International Conference on Harmonization guidelines. The calibration curves were linear over a range of 0.1–15 µg/mL for octreotide and 0.20‐15 µg/mL for gabexate mesylate metabolite. Derivatized products of octreotide and gabexate mesylate metabolite were separated on a Luna C₁₈ column (4.6 × 250 mm; 5 µm particle size) using a gradient with a run time of 36 min, without further purification. The limits of detection were 0.025 and 0.05, respectively, for octreotide and gabexate mesylate metabolite. This paper reports the validation of a quantitative high performance liquid chromatography–photodiode array–fluorescence (HPLC‐PDA‐FL) method for the simultaneous analysis of octreotide and gabexate mesylate metabolite in pancreatic juice by protein precipitation using zinc sulfate–methanol–acetonitrile containing the derivatizing reagent, 4‐fluoro‐7‐nitro‐[2,1,3]‐benzoxadiazole (NBD‐F). Derivatized products of octreotide and gabexate mesylate metabolite were separated on a Luna C₁₈ column (4.6 × 250 mm; 5 µm particle size) using a gradient with a run time of 36 min, without further purification. The method was validated over the concentration ranges 0.1–15 and 0.2–15 µg/mL for octreotide and gabexate mesylate metabolite, respectively, in human pancreatic juice. Biphalin and methyl‐p‐hydroxybenzoate were used as the internal standards. This method was successfully utilized to support clinical studies in humans. The results from assay validations show that the method is selective, sensitive and robust. The limit of quantification of the method was 0.1 µg/mL for octreotide and 0.2 µg/mL for gabexate mesylate metabolite, and matrix matched standard curves showed a good linearity up to 15 µg/mL. In the entire analytical range the intra‐ and inter‐day precision (RSD%) values were respectively ≤5.9% and ≤3.1% for octreotide and ≤2.0% and ≤3.9% for gabexate mesylate metabolite. For both analytes the intra‐ and inter‐day accuracy (bias) values ranged respectively from ?6.8 to –2.5% and from ?4.6 to ?5.7%. This method utilizes derivatization with NBD‐F and provides adequate sensitivity for both drugs. Copyright © 2014 John Wiley & Sons, Ltd.     

Randomized two‐way cross‐over bioequivalence study of two amoxicillin formulations and inter‐ethnicity pharmacokinetic variation in healthy Malay volunteers

The objectives of this study were to develop a new deproteinization method to extract amoxicillin from human plasma and evaluate the inter‐ethnic variation of amoxicillin pharmacokinetics in healthy Malay volunteers. A single‐dose, randomized, fasting, two‐period, two‐treatment, two‐sequence crossover, open‐label bioequivalence study was conducted in 18 healthy Malay adult male volunteers, with one week washout period. The drug concentration in the sample was analyzed using high‐performance liquid chromatography (UV–vis HPLC). The mean (standard deviation) pharmacokinetic parameter results of Moxilen® were: peak concentration (C_max), 6.72 (1.56) µg/mL; area under the concentration–time graph (AUC_0–8), 17.79 (4.29) µg/mL h; AUC_0–∞, 18.84 (4.62) µg/mL h. Those of YSP Amoxicillin® capsule were: C_max, 6.69 (1.44) µg/mL; AUC_0–8, 18.69 (3.78) µg/mL h; AUC0_0–∞, 19.95 (3.81) µg/mL h. The 90% confidence intervals for the logarithmic transformed C_max, AUC_0–8 and AUC_0–∞ of Moxilen® vs YSP Amoxicillin® capsule was between 0.80 and 1.25. Both C_max and AUC met the predetermined criteria for assuming bioequivalence. Both formulations were well tolerated. The results showed significant inter‐ethnicity variation in pharmacokinetics of amoxicillin. The C_max and AUC of amoxicillin in Malay population were slightly lower compared with other populations. Copyright © 2014 John Wiley & Sons, Ltd.     

Simultaneous determination of norisoboldine and its major metabolite in rat plasma by ultra-performance liquid chromatography-mass spectrometry and its application in a pharmacokinetic study

Norisoboldine (NIB) is one of the main bioactive isoquinoline alkaloids in Linderae Radix. A rapid, selective and sensitive method using UPLC‐ESI/MS was first developed for simultaneous determination of NIB and norisoboldine‐9‐O‐α‐glucuronide (NIB‐Glu), its major metabolite in rat plasma. A one‐step protein precipitation with methanol was employed as sample preparation technique. Chromatographic separation was carried out on an Acquity UPLC BEH C₁₈ column (50 × 2.1 mm, i.d. 1.7 µm) with a gradient mobile phase consisting of acetonitrile and water containing 0.1% formic acid. Detection and quantification were performed using a quadrupole mass spectrometer by selective ion reaction‐monitoring mode. Good linearity was achieved using weighted (1/x²) least squares linear regression over the concentration ranges 0.01–2 µg/mL for NIB and 0.025–25 µg/mL for NIB‐Glu. The lower limit of quantification of NIB and NIB‐Glu was 0.01 and 0.025 µg/mL, respectively. The intra‐ and inter‐day precisions (relative standard deviations) of the assay at all three quality control levels were 4.6–14.1% for NIB, and 5.0–12.2% for NIB‐Glu. The accuracies (relative error) were −13.5–8.1% for NIB and −12.8–7.6% for NIB‐Glu, respectively. This developed method was successfully applied to an in vivo pharmacokinetic study in rats after a single intravenous dose of 10 mg/kg NIB. Copyright © 2010 John Wiley & Sons, Ltd.     

Rapid determination and comparative pharmacokinetics of tetrahydropalmatine in spontaneously hypertensive rats and normotensive rats

A rapid high‐performance liquid chromatographic method was developed and validated for determination of tetrahydropalmatine (THP), an active component of Rhizoma Corydalis, in rat plasma. The samples were prepared using protein precipitation and separated on an Agilent XDB‐C₁₈ column (150 × 4.6 mm, 5 µm) with the mobile phase consisting of methanol–0.1% phosphate acid solution, adjusted with triethylamine to pH 5.5 (65:35). Good linearity was found within 0.10–10.00 µg/mL of THP in rat plasma sample. The intra‐ and inter‐day precision values were less than 10%. The developed method was successfully applied to assess the pharmacokinetics of THP in spontaneously hypertensive rats (SHR) and normotensive rats. After oral administration of a single dose of THP (60 mg/kg), the maximum plasma concentrations were 6.15 ± 2.1 and 7.54 ± 2.9 µg/mL for normotensive rats and SHR, respectively. The mean values of AUC_0–∞ of THP in SHR were 81.44 ± 45.0 µg h/mL, significantly higher (p < 0.05) than in normotensive rats (44.06 ± 19.6 µg h/mL). The t_1/2 and MRT in SHR were much longer than that in healthy Sprague–Dawley rats, indicating slow elimination of THP in SHR. The results indicated that there are some differences in pharmacokinetics of THP in SHR and Sprague–Dawley rats and it is very important to investigate the pharmacokinetic properties of drugs in pathological conditions. Copyright © 2011 John Wiley & Sons, Ltd.     

Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma

Caffeine has been extensively used as a probe to measure CYP1A2 activity in humans with caffeine clearance or the paraxanthine (major metabolite of caffeine) to caffeine concentration ratio being regarded as the preferred metric. A simple reverse‐phased C₁₈ HPLC assay using ethyl acetate liquid–liquid extraction was developed to quantitate caffeine and paraxanthine concentrations in saliva and plasma. The mobile phase consisted of acetonitrile–acetic acid–H₂O (100:1:899) and analytes were quantitated with UV detection at 280 nm. The extraction recovery for paraxanthine and caffeine was approximately 70% in both saliva and plasma. The assay was linear over the concentration ranges 0.05–2.50 and 0.05–5.00 µg/mL, for paraxanthine and caffeine, respectively, in saliva. In plasma the assay was linear over the ranges 0.025–2.50 and 0.025–5.00 µg/mL for paraxanthine and caffeine, respectively. Intra‐ and inter‐assay precision and accuracy were less than 15%. Detection limits were 0.015 µg/mL for paraxanthine and caffeine in saliva, while it was 0.005 µg/mL for paraxanthine and caffeine in plasma. Utility was established in samples collected from two healthy volunteers who abstained from caffeine for 24 h and received a single 100 mg oral dose of caffeine. The assay developed is a robust, simple and precise technique to measure caffeine and paraxanthine in saliva and plasma of healthy volunteers after a single oral dose of caffeine. Copyright © 2010 John Wiley & Sons, Ltd.     

Determination of a novel paclitaxel derivative (NPD‐103) in human plasma by ultra‐performance liquid chromatography–tandem mass spectrometry

A sensitive and specific ultra‐performance liquid chromatography–tandem mass spectrometry (UPLC‐MS‐MS) method for quantification of a newly developed anticancer agent NPD‐103 has been established. An aliquot of human plasma sample (200 µL) was spiked with ¹³C‐labeled paclitaxel (internal standard) and extracted with 1.3 mL of tert‐butyl methyl ether. NPD‐103 was quantitated on a C₁₈ column with methanol–0.1% formic acid (75:25, v/v) as mobile phase using UPLC‐MS‐MS operating in positive electrospray ionization mode with a total run time of 3.0 min. For NPD‐103 at the concentrations of 1.0, 5.0 and 10.0 µg/mL in human plasma, the absolute extraction recoveries were 95.58, 102.43 and 97.77%, respectively. The linear quantification range of the method was 0.1–20.0 µg/mL in human plasma with linear correlation coefficients greater than 0.999. The intra‐ and inter‐day accuracy for NPD‐103 at 1.0, 5.0 and 10.0 µg/mL levels in human plasma fell into the ranges of 95.29–100.00% and 91.04–94.21%, and the intra‐ and inter‐day precisions were in the ranges of 8.96–11.79% and 7.25–10.63%, respectively. This assay is applied to determination of half‐life of NPD‐103 in human plasma. Copyright © 2008 John Wiley & Sons, Ltd.     

Highly Sensitive Differential Pulse and Square Wave Voltammetric Methods for Determination of Strontium Ranelate in Bulk and Pharmaceutical Dosage Form

The voltammetric behavior of Strontium Ranelate (SR) was studied using Cyclic (CV), differential pulse (DPV) and square wave (SWV) voltammetry. CV showed two well‐defined, irreversible, diffusion‐controlled anodic peaks using Britton‐Robinson buffer, pH 2.0 at Pencil graphite (PGE), Carbon paste (CPE) and glassy carbon (GCE) electrodes. The peak current‐concentration relationship was rectilinear over the range 1.0–10.0, 1.0–11.25 and 2.5–24.0 µg/mL at PGE, CPE and GCE respectively, with a minimum detectability of 0.17, 0.24 and 0.39 µg/mL for peak 1 and 0.19, 0.27 and 0.51 µg/mL for peak 2. Recoveries showed the high accuracy of the method; 99.8 %, 99.5 % and 99.7 % at PGE, CPE and GCE respectively for peak 1 and 100.1 %, 99.9 % and 99.7 % at PGE, CPE and GCE respectively for peak 2. Hence DPV and SWV were conducted for the quantitative determination of SR in its pure and pharmaceutical dosage form. the method was validated and the results were in good agreement with those obtained from the reported method.     

Permeation associated with three-phase-partitioning method on release of green fluorescent protein

Transformed cells of Escherichia coli expressing recombinant green fluorescent protein (GFPuv) were subjected to two methods of extraction: (1) freezing/thawing/sonication (FTS) cycles prior to the three-phase partitioning (TPP) method, or (2) directly to TPP extraction. The amount of GFPuv released by the FTS plus TPP method varied: 374μg/mL (first cycle), 93–442 μg/mL (second cycle), 32–359 μg/mL (third cycle), 18–115 μg/mL (fourth cycle). The GFPuv yields by the second method (TPP only) were, 23–54 μg/mL for the first extract and 33–91 μg/mL for the second. The FTS plus TPP method released similar amounts of GFPuv to that extracted by TPP; and provided a better mixture elution through the hydrophobic interaction column: 13–63 μg/mL for FTS plus TPP methods, and 2.5–13 μg/mL for TPP. The results showed that although selective permeation is a more laborious methodology, it was more efficient for obtaining of GFPuv in relation to the direct extraction of the cells for TPP.     

Gas chromatography–electron ionization–mass spectrometry quantitation of valproic acid and gabapentin,using dried plasma spots,for therapeutic drug monitoring in in‐home medical care

A simple and sensitive gas chromatography–electron ionization–mass spectrometry (GC‐EI‐MS) method using dried plasma spot testing cards was developed for determination of valproic acid and gabapentin concentrations in human plasma from patients receiving in‐home medical care. We have proposed that a simple, easy and dry sampling method is suitable for in‐home medical patients for therapeutic drug monitoring. Therefore, in the present study, we used recently developed commercially available easy handling cards: Whatman FTA DMPK‐A and Bond Elut DMS. In‐home medical care patients can collect plasma using these simple kits. The spots of plasma on the cards were extracted into methanol and then evaporated to dryness. The residues were trimethylsilylated using N‐methyl‐N‐trimethylsilyltrifluoroacetamide. For GC‐EI‐MS analysis, the calibration curves on both cards were linear from 10 to 200 µg/mL for valproic acid, and from 0.5 to 10 µg/mL for gabapentin. Intra‐ and interday precisions in plasma were both ≤13.0% (coefficient of variation), and the accuracy was between 87.9 and 112% for both cards within the calibration curves. The limits of quantification were 10 µg/mL for valproic acid and 0.5 µg/mL for gabapentin on both cards. We believe that the present method will be useful for in‐home medical care. Copyright © 2014 John Wiley & Sons, Ltd.     

Simultaneous determination of baicalin,oroxylin A‐7‐O‐glucuronide and wogonoside in rat plasma by UPLC‐DAD and its application in pharmacokinetics of pure baicalin,Radix Scutellariae and Yinhuang granule

A novel UPLC‐DAD method was developed and validated for the simultaneous determination of baicalin (baicalein‐7‐glucuronide, BG), oroxylin A‐7‐O‐glucuronide (OAG) and wogonoside (WG) in rat plasma using rutin as the internal standard. Plasma samples were precipitated using acetonitrile containing 0.1% formic acid. Separation was performed on an Agilent Eclipse Plus C₁₈ column (2.1 × 50 mm, 1.8 µm) using gradient acetonitrile and 0.2% formic acid water solution as mobile phase. The flow‐rate was set at 0.4 mL/min and the eluate was detected at 275 nm. The method was linear over the ranges of 0.075–17.50, 0.050–12.60 and 0.056–14.10 µg/mL for BG, OAG and WG, respectively. The intra‐ and inter‐day precisions were respectively <4.8% and 6.4%. All of the limits of detection of three analytes in rat plasma were 0.01 µg/mL, whereas the limits of quantification were, respectively, 0.035, 0.025 and, 0.025 µg/mL. This assay has been successfully applied to pharmacokinetics of BG, OAG and WG in rats after oral administration of Yinhuang granule (YHG) and comparative pharmacokinetics of BG in rats following oral administration of the pure BG, Radix Scutellariae (RS) or YHG. We speculate that some co‐existing ingredients in RS or YHG may increase the absorption and elimination of BG in rat. This work may be helpful for the quality control of Yinhuang granule. Copyright © 2015 John Wiley & Sons, Ltd.     

Determination of piracetam in rat plasma by LC–MS/MS and its application to pharmacokinetics

A sensitive and selective liquid chromatography–tandem mass spectrometry method for the determination of piracetam in rat plasma was developed and validated over the concentration range of 0.1–20 µg/mL. After addition of oxiracetam as internal standard, a simplified protein precipitation with trichloroacetic acid (5%) was employed for the sample preparation. Chromatographic separation was performed by a Zorbax SB‐Aq column (150 × 2.1 mm, 3.5 µm). The mobile phase was acetonitrile–1% formic acid in water (10:90 v/v) delivered at a flow rate of 0.3 mL/min. The MS data acquisition was accomplished in multiple reaction monitoring mode with a positive electrospray ionization interface. The lower limit of quantification was 0.1 µg/mL. For inter‐day and intra‐day tests, the precision (RSD) for the entire validation was less than 9%, and the accuracy was within the 94.6–103.2% range. The developed method was successfully applied to pharmacokinetic studies of piracetam in rats following single oral administration dose of 50 mg/kg. Copyright © 2010 John Wiley & Sons, Ltd.     

Simultaneous Determination of Levomepromazine Hydrochloride and Its Sulfoxide by UV‐Derivative Spectrophotometry and Bivariate Calibration Method

Abstract

Two spectrophotometric methods are proposed for the simultaneous quantification of levomepromazine hydrochloride (LV) and its main degradation product levomepromazine sulfoxide (LV‐SO). One of them is based on the first order derivative spectra generated by the Savitzky‐Golay algorithm (third‐order polynomial degree, Δλ=10 nm). Determination of levomepromazine hydrochloride and its sulfoxide was realized by measurements of amplitudes of derivative spectra at 332 nm and 278 nm, respectively. The Beer law was obeyed in the concentration range 1.5–50 µg/mL for LV and 2.5–50 µg/mL for LV‐SO. The second of the proposed methods utilized the bivariate calibration algorithm. The determination was performed at 302 nm for levomepromazine and at 334 nm for sulfoxide. The elaborated methods allowed determination of LV in the concentration range 1.0–25 µg/mL while LV‐SO was determined in the concentration range 2.0–50 µg/mL.     

Synthesis of 3,5-Dichloro-4-(1,1,2,2-tetrafluoroethoxy)phenyl Containing 1,2,3-Thiadiazole Derivatives via Ugi Reaction and Their Biological Activities

A series of novel 3,5‐dichloro‐4‐(1,1,2,2‐tetrafluoroethoxy)phenyl containing 4‐methyl‐1,2,3‐thiadiazole derivatives were designed and synthesized via Ugi reaction. Their structures were confirmed by IR, ¹H NMR, ¹³C NMR and high‐resolution mass spectroscopy. The preliminary bioassay results indicated that some title compounds had good fungicide activity at 50 µg/mL; most of the compounds presented a certain degree of direct inhibition activity, good inactivation and curative activity against tobacco mosaic virus at 500 µg/mL and 100 µg/mL; some compounds showed good larvicidal activity against Plutella xylostella L. at 200 µg/mL and excellent larvicidal activities against Culex pipiens pallens at 2 µg/mL.     

A chiral liquid chromatography method for the simultaneous determination of oxcarbazepine, eslicarbazepine, R-licarbazepine and other new chemical derivatives BIA 2-024, BIA 2-059 and BIA 2-265, in mouse plasma and brain

Recently, in silico models have been developed to predict drug pharmacokinetics. However, before application, they must be validated and, for that, information about structurally similar reference compounds is required. A chiral liquid chromatography method with ultraviolet detection (LC‐UV) was developed and validated for the simultaneous quantification of BIA 2–024, BIA 2–059, BIA 2–265, oxcarbazepine, eslicarbazepine (S‐licarbazepine) and R‐licarbazepine in mouse plasma and brain. Compounds were extracted by a selective solid‐phase extraction procedure and their chromatographic separation was achieved on a LiChroCART 250–4 ChiraDex column using a mobile phase of water–methanol (92:8, v/v) pumped at 0.7 mL/min. The UV detector was set at 235 nm. Calibration curves were linear (r² ≥ 0.996) over the concentration ranges of 0.2–30 µg/mL for oxcarbazepine, eslicarbazepine and R‐licarbazepine; 0.2–60 µg/mL for the remaining compounds in plasma; and 0.06–15 µg/mL for all the analytes in brain homogenate. Taking into account all analytes at these concentration ranges in both matrices, the overall precision did not exceed 9.09%, and the accuracy was within ±14.3%. This LC‐UV method is suitable for carrying out pharmacokinetic studies with these compounds in mouse in order to obtain a better picture of their metabolic pathways and biodistribution. Copyright © 2011 John Wiley & Sons, Ltd.